Innocan Pharma Reports Successful Results of Efficacy Test for Vaginal Derma Product

March 23, 2023 4:00 AM EDT | Source: Innocan Pharma Corporation

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 23, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative wellness products, announced today the successful results of a controlled efficacy test (the "Trial") regarding its vaginal derma product (the "Product").

The results of the Trial demonstrate that Innocan's Product, which contains cannabinoids, phytoestrogens, hyaluronic acid, and probiotics, effectively reduced the symptoms, and improved overall vaginal health.

The 56-day Trial was conducted with a group of female volunteers experiencing symptoms of vaginal dryness, stinging, burning, infection, and pain during urination.

The primary indication of the Trial was a statistically significant alleviation of symptoms after 28 days of Product use including:

Percentage improvement Compared to T0Symptoms
66%Vaginal burning
64%Pruritus (Itching)
47%Vaginal dryness
59%Pain during intercourse
63%Urinary discomfort


Furthermore, 94% of the volunteers reported a reduction in vaginal dryness, 94% indicated better sensation during intimate relationships, and 91% stated that the vaginal area became more elastic. Additionally, 93% of the volunteers reported a reduction in discomfort during sports activity, 94% felt immediate relief from vaginal itching, 93% felt their skin was healthier, and 97% would recommend the Product to others.

The Product does not contain hormones or steroids, which are commonly used to treat similar symptoms and can have negative side effects. Innocan's use of cannabinoids and other natural ingredients offers a healthy alternative for women seeking relief from vaginal discomfort.

"We are thrilled with the results of this efficacy test and the positive impact our product had on the women who participated," said Iris Bincovich, CEO of Innocan. "Our focus is on developing safe and effective products that can improve the quality of life for people in need, and we are proud to achieve such promising results with our vaginal derma product."

About Innocan

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients' quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. (ii) CLX CBD-loaded exosomes platform that may hold the potential to provide a highly synergistic effect of regenerating and anti- inflammatory properties targeting the Central Nervous System (CNS). In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO


Dr. Eva Reuter
Investment Relation- Germany


Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

To view the source version of this press release, please visit